VISALIA, Calif. January 24, 2013 – Edeniq, Inc., a biomaterials and sustainable fuels company, today
announced Dr. Dan Michalopoulos as a key new addition to the company’s core technology team. Dr.
Michalopoulos brings over 20 years of experience in both business and academia across chemical
technology and alternative fuels sectors to his new role at Edeniq.
To read the full release please click here
The information and material presented are informational only and do not constitute an offer to sell, or a solicitation of an offer to buy, securities or interests in any fund or fund product. Investors must meet certain qualifications for the purchase of alternative investments and must meet other selection criteria. Investments in I2BF Group funds are only offered through confidential private placement memorandums or prospectuses which are not available on this website. There can be no assurance that an investment in any investment product will achieve profits or avoid incurring substantial losses. There is a high degree of risk inherent in alternative investments and they are not be suitable for all eligible investors. Investors purchasing alternative investment products may lose some or all of their investment. Before making an investment decision, please carefully (i) consider the suitability of alternative investments with respect to your investment objectives and personal situation and (ii) consider factors such as its personal net worth, income, age, risk tolerance, and liquidity needs. Short-term investors and investors who cannot bear the loss of some or all of their investment or the risks associated with the limited liquidity of an investment should not invest.